Lmr Partners LLP Black Diamond Therapeutics, Inc. Transaction History
Lmr Partners LLP
- $9.66 Billion
- Q4 2024
A detailed history of Lmr Partners LLP transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Lmr Partners LLP holds 30,100 shares of BDTX stock, worth $53,578. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,100
Previous 206,400
85.42%
Holding current value
$53,578
Previous $897,000
92.87%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding BDTX
# of Institutions
94Shares Held
47.6MCall Options Held
2.9KPut Options Held
69.4K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.5MShares$18.6 Million0.01% of portfolio
-
Bellevue Group Ag Kuesnacht, V88.52MShares$15.2 Million0.36% of portfolio
-
Vestal Point Capital, LP New York, NY5.6MShares$9.97 Million0.71% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$7.92 Million0.68% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$5.73 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $64.7M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...